Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
deals
10
×
fda
10
×
life sciences
national blog main
biotech
clinical trials
boston blog main
boston top stories
national top stories
san francisco blog main
investing
new york blog main
san francisco top stories
boston
new york top stories
raleigh-durham blog main
san diego blog main
san diego top stories
startups
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham top stories
rna interference
roche
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alexion pharmaceuticals
cancer
cancer immunotherapy
drugs
What
drug
10
×
medicines
disease
fda
deal
roundup
therapeutics
approved
bio
cancer
candidate
cash
company
gene
news
pharma
pharmaceuticals
potential
roche
team
therapy
acquire
affects
agreed
ahead
alternative
ambien
american
americans
annual
approval
aren’t
asco
attendees
attention
autoimmune
bacteria
billion
biopharma
biotech
Language
unset
Current search:
fda
×
drug
×
deals
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
5 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed